Conduit Pharmaceuticals Stock Performance
| CDT Stock | 0.90 0.07 8.43% |
The firm shows a Beta (market volatility) of -6.23, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Conduit Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Conduit Pharmaceuticals is expected to outperform it. At this point, Conduit Pharmaceuticals has a negative expected return of -1.85%. Please make sure to confirm Conduit Pharmaceuticals' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Conduit Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Conduit Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:100 | Last Split Date 2025-01-27 |
1 | Acquisition by Fromm Charles of 15700 shares of Conduit Pharmaceuticals at 10.0 subject to Rule 16b-3 | 01/10/2025 |
2 | Student, teacher AI use continued to climb in 2023-24 school year | 01/15/2025 |
3 | Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - The Manila Times | 01/23/2025 |
4 | Conduit Pharmaceuticals Stock Set to Reverse Split on Monday, January 27th | 01/24/2025 |
5 | Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug ... | 01/28/2025 |
6 | Disposition of tradable shares by Regan Andrew of Conduit Pharmaceuticals subject to Rule 16b-3 | 02/07/2025 |
7 | Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus ... | 02/13/2025 |
8 | Conduit Progresses Phase II of its AI Initiative with Sarborg | 02/20/2025 |
9 | Is Conduit Pharmaceuticals Inc. the Best Micro Cap Stock to Buy Now | 03/07/2025 |
10 | Why Is Conduit Pharmaceuticals Stock Up 123 percent Today - MSN | 03/20/2025 |
| Begin Period Cash Flow | 597 M | |
| Free Cash Flow | 223 M |
Conduit |
Conduit Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 590.00 in Conduit Pharmaceuticals on December 24, 2024 and sell it today you would lose (500.00) from holding Conduit Pharmaceuticals or give up 84.75% of portfolio value over 90 days. Conduit Pharmaceuticals is generating negative expected returns assuming volatility of 16.9031% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than Conduit, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Conduit Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Conduit Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Conduit Pharmaceuticals, and traders can use it to determine the average amount a Conduit Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1092
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CDT |
Estimated Market Risk
| 16.9 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.85 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Conduit Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Conduit Pharmaceuticals by adding Conduit Pharmaceuticals to a well-diversified portfolio.
Conduit Pharmaceuticals Fundamentals Growth
Conduit Stock prices reflect investors' perceptions of the future prospects and financial health of Conduit Pharmaceuticals, and Conduit Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Conduit Stock performance.
| Return On Asset | -1.09 | ||||
| Current Valuation | 7.6 M | ||||
| Shares Outstanding | 6.2 M | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B | ||||
| Book Value Per Share | (9.50) X | ||||
| Cash Flow From Operations | 344.8 M | ||||
| Earnings Per Share | (23.00) X | ||||
| Market Capitalization | 5.12 M | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 1.18 B | ||||
| Working Capital | 3.93 M | ||||
About Conduit Pharmaceuticals Performance
Assessing Conduit Pharmaceuticals' fundamental ratios provides investors with valuable insights into Conduit Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Conduit Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 73.25 | 65.10 | |
| Return On Tangible Assets | 0.11 | 0.11 | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.15 | 0.15 |
Things to note about Conduit Pharmaceuticals performance evaluation
Checking the ongoing alerts about Conduit Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Conduit Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Why Is Conduit Pharmaceuticals Stock Up 123 percent Today - MSN |
- Analyzing Conduit Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Conduit Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Conduit Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Conduit Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Conduit Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Conduit Pharmaceuticals' stock. These opinions can provide insight into Conduit Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.